List of Excipients in Branded Drug DESONATE

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Intendis Inc	DESONATE	desonide	10922-828	EDETATE DISODIUM
Intendis Inc	DESONATE	desonide	10922-828	GLYCERIN
Intendis Inc	DESONATE	desonide	10922-828	METHYLPARABEN

Desonate Excipient Strategy and Commercial Opportunities in Desonide 0.05% Gel

Last updated: September 24, 2026

Desonate is a prescription topical hydrogel containing desonide 0.05%, a low-potency corticosteroid indicated for mild-to-moderate atopic dermatitis in patients three months of age and older. Its commercial value is concentrated in pediatric tolerability, cosmetic acceptability, vehicle performance, and substitution opportunities rather than in active-ingredient exclusivity. The strongest product strategies are preservative-reduced or preservative-free gels, improved metered delivery, lower-irritancy excipient systems, and differentiated generic or branded-generic presentations.

What is Desonate and how is it formulated?

Desonate is a topical gel marketed at a desonide concentration of 0.05% w/w. The reference product is a clear, colorless, translucent hydrogel intended for application to affected skin. Its label identifies the following inactive ingredients:

Excipient	Primary formulation function
Carbomer 934P	Gel-forming polymer and rheology modifier
Edetate disodium	Chelating agent and preservative-support excipient
Glycerin	Humectant and skin-feel modifier
Methylparaben	Antimicrobial preservative
Propylene glycol	Solvent, humectant and penetration-enhancing excipient
Purified water	Continuous aqueous phase
Sodium hydroxide	pH adjustment and carbomer neutralization

The formulation architecture is conventional for a dermatologic corticosteroid gel. Carbomer creates the semisolid matrix after neutralization with sodium hydroxide. Propylene glycol and glycerin support solubilization and hydration. Edetate disodium improves preservative robustness by binding metal ions that can support microbial growth or accelerate degradation. Methylparaben provides antimicrobial protection. [1]

The reference formulation creates several development constraints. Carbomer concentration and neutralization materially affect viscosity, spreadability, drug release and package dispensing. Propylene glycol can improve solubilization and skin penetration, but may produce stinging or irritation in compromised skin. Methylparaben provides practical preservative protection but creates a differentiation opportunity for products designed for preservative-sensitive pediatric users.

What excipient strategy is most attractive for Desonate competitors?

The highest-value strategy is a controlled reformulation that preserves the clinical and release profile of the reference product while improving tolerability and user experience.

Preservative-free aqueous gel

A preservative-free formulation could replace methylparaben with a package-based microbiological control system, such as:

• An airless pump that limits repeated air exchange.
• A unit-dose sachet or tube presentation.
• A low-water-activity gel system.
• A validated single-use dispenser.
• A sterile or aseptically filled presentation where commercially justified.

A conventional multidose tube containing a high-water-content gel generally requires robust antimicrobial protection. Removing methylparaben without changing the packaging and manufacturing process would create microbiological risk. The commercial opportunity therefore lies in coordinated formulation and container-closure development, not in simple deletion of the preservative.

A preservative-free claim may be valuable in pediatric dermatology, but it creates additional stability, microbial challenge, packaging and manufacturing requirements. The product must demonstrate that the new system maintains potency, impurity control, physical stability, microbial quality and in-use performance.

Reduced-propylene-glycol formulation

Propylene glycol is useful in desonide gels because it can function as a solvent and penetration aid. It can also contribute to burning or irritation, particularly on fissured or inflamed skin. A lower-propylene-glycol or propylene-glycol-free formulation could target:

• Infants and young children.
• Patients with barrier-impaired skin.
• Facial and intertriginous application.
• Patients who discontinue treatment because of stinging.
• Products positioned around sensitive-skin tolerability.

Potential replacement systems include glycerin, propanediol, butylene glycol, polyethylene glycol grades or other pharmaceutically acceptable cosolvents. The principal technical risk is loss of desonide solubilization or a change in thermodynamic activity. That can alter crystallization, dermal delivery and IVRT performance.

A lower-irritancy formulation should not be evaluated only by appearance and viscosity. It requires comparative drug-release testing, microscopy for recrystallization, accelerated stability, skin irritation testing and, where appropriate, clinical bridging.

Polymer and rheology optimization

Carbomer is central to the Desonate gel profile. A competitor can differentiate through:

• Lower tack.
• Faster rub-in.
• Improved spreadability.
• Reduced pilling under sunscreen or moisturizer.
• Better pumpability.
• More consistent dosing across temperature conditions.
• Improved residence time without an occlusive ointment feel.

Alternative polymers include acrylates/C10-30 alkyl acrylate crosspolymers, poloxamers, cellulose derivatives and associative thickeners. Each option affects pH response, electrolyte sensitivity, yield stress and drug release.

A formulation that is too viscous may reduce patient adherence and make pediatric application difficult. A formulation that is too fluid may run from the application site and produce inconsistent dosing. The target should be a stable, easily spread hydrogel with a rheology profile close enough to the reference product to support regulatory comparability while offering a measurable user-experience advantage.

Humectant and skin-barrier positioning

Glycerin is already present in Desonate and supports hydration. A differentiated formulation could increase humectancy or combine glycerin with a barrier-supportive excipient such as panthenol, low-level ceramide technology or a compatible emollient phase. This strategy has limits.

Desonate is approved as a drug product, not as a cosmetic moisturizer. Added excipients cannot introduce unacceptable irritation, alter drug delivery unpredictably or create a new clinical claim that requires additional evidence. A barrier-supportive formulation is most commercially credible when it improves use characteristics without changing the product’s core corticosteroid indication.

What formulation patents could protect a new Desonate product?

Formulation protection is more relevant than desonide composition-of-matter protection because desonide is an established corticosteroid. Potential claim categories include:

Claim category	Commercial relevance
Preservative-free multidose gel	Protects excipient and container-closure combination
Low-propylene-glycol gel	Supports sensitive-skin differentiation
Specific carbomer concentration and neutralization range	Protects rheology and release profile
Hydrogel with defined desonide particle or solubility characteristics	Targets physical stability and delivery
Airless pump or metered-dose dispenser	Protects dosing and microbiological-control architecture
Combination of desonide with barrier-supportive excipients	Supports premium positioning
Manufacturing process	Protects dispersion, neutralization and deaeration sequence
Use in pediatric or sensitive-skin populations	May support method-of-use protection if legally eligible

A strong patent should connect the excipient system to a measurable technical result. Examples include improved desonide stability, lower crystallization, controlled release, reduced irritation, improved microbial robustness or more consistent delivered dose.

Claims directed only to routine substitution of one humectant for another are vulnerable to obviousness challenges. Stronger protection generally requires a defined composition window, an unexpected performance result and a reproducible manufacturing process.

Patent owners and applicants should also assess freedom to operate around carbomer grades, preservative-free packaging, airless dispensers, topical corticosteroid vehicles and manufacturing methods. Orange Book listing depends on the scope and type of patent and does not automatically apply to every formulation patent. [2]

What is the FDA regulatory status of Desonate?

Desonate was approved by the FDA under NDA 021844 as a prescription topical product containing desonide 0.05% gel. The labeled indication covers mild-to-moderate atopic dermatitis in patients three months of age and older. Treatment is generally limited to affected areas and short-duration use consistent with low-potency topical corticosteroid labeling. [1]

A generic competitor would typically pursue an abbreviated new drug application under the applicable topical dermatologic pathway. FDA approval depends on pharmaceutical equivalence and the evidence required for the product and dosage form. For semisolid topical products, development may require:

• Q1 qualitative sameness or an accepted difference.
• Q2 quantitative sameness where required.
• Comparative physicochemical characterization.
• In vitro release testing.
• In vitro permeation testing where relevant.
• Microbiological quality and preservative-effectiveness data.
• Product-performance testing.
• Stability studies.
• Container-closure compatibility.
• FDA-required clinical or pharmacodynamic evidence if the product cannot be adequately supported through comparative characterization.

The excipient strategy should be selected with the regulatory pathway in mind. A Q1/Q2-aligned generic may reduce development risk but offer limited differentiation. A novel excipient system may produce stronger commercial positioning but increase the burden of comparative performance and clinical support.

What Orange Book and exclusivity issues affect Desonate?

Desonate’s active ingredient, desonide, is an established corticosteroid. The commercial question is therefore not whether desonide remains protected as a new chemical entity. The relevant questions are whether formulation, method-of-use or packaging patents remain listed, whether regulatory exclusivity remains active, and whether approved generic versions are already available.

For a current transaction or launch decision, the FDA Orange Book should be reviewed for:

1. NDA 021844.
2. Any listed patents.
3. Patent expiration dates.
4. Delisting or expiration events.
5. Approved dosage-form and strength entries.
6. Generic applicants and therapeutic-equivalence ratings.

The principal generic-entry risk is usually formulation substitution rather than an active-ingredient challenge. A Paragraph IV certification could arise if an applicant seeks approval before an asserted listed patent expires. The commercial impact would depend on the patent’s claim scope, the timing of litigation and any settlement restrictions. [2][3]

A formulation patent with claims limited to a narrow gel composition may have less defensive value than a patent covering a commercially necessary feature, such as a specific vehicle, delivery system or manufacturing process. Method-of-use patents covering pediatric atopic dermatitis may also be relevant, but their ability to block a full generic label depends on listing status, claim scope and the applicant’s proposed labeling strategy.

When does Desonate lose exclusivity and what generic launch scenarios exist?

Desonate has the profile of a mature topical product. Generic competition can enter through several pathways:

Direct generic substitution

A generic desonide 0.05% gel with an FDA therapeutic-equivalence rating can compete primarily on reimbursement, wholesaler access and pharmacy substitution. This is the highest-probability erosion scenario for the reference product.

Value-priced branded generic

A manufacturer can retain some price premium through:

• Better dispensing.
• Preservative reduction.
• Improved pediatric tolerability.
• More convenient package sizes.
• Contracting with managed-care plans.
• Dermatology-focused promotion.

Reformulated prescription product

A reformulated product could seek a separate NDA or other regulatory pathway if its composition and claims materially differ from the reference product. It could compete on vehicle performance rather than price.

Compounded alternatives

Compounding pharmacies can prepare desonide topical products, but compounded products do not automatically have the same quality, stability, labeling or substitution status as an FDA-approved generic. Compounding is more likely to affect niche demand than to replace an approved commercial gel across major channels.

What commercial opportunities exist in the Desonate market?

The strongest opportunities are concentrated in premium topical dermatology and pediatric adherence.

Opportunity	Commercial thesis	Main risk
Preservative-free gel	Appeals to sensitive-skin and pediatric use	Packaging and microbiological burden
Airless metered pump	Improves dose consistency and hygiene	Higher device cost
Low-irritancy vehicle	Reduces stinging and discontinuation	Possible change in drug delivery
Lower-tack gel	Improves cosmetic acceptability	May reduce residence time
Larger economy package	Supports chronic or recurrent disease use	Lower unit revenue
Pediatric-oriented presentation	Differentiates through usability	Limited ability to command premium
Pharmacy-compounded base platform	Enables customization	Quality and scalability limits
International licensing	Expands regional access to a mature API	Local registration and price controls

Revenue exposure is driven by unit volume, payer coverage and generic substitution. The reference product’s price premium is vulnerable where pharmacies can substitute an approved generic. A differentiated vehicle can preserve revenue only if the clinical or adherence benefit is clear enough to influence prescribers, patients or payers.

Potential licensing partners include dermatology-focused pharmaceutical companies, generic manufacturers with topical manufacturing capability, contract development and manufacturing organizations, and device companies with airless or metered topical delivery platforms. The most valuable deal structure would combine formulation IP, regulatory know-how, manufacturing transfer and regional commercialization rights.

How strong is the patent estate for a new Desonate formulation?

Patent strength depends on five factors:

1. The formulation contains a non-routine excipient combination.
2. The claims define narrow but commercially important composition ranges.
3. The specification shows unexpected performance.
4. The product has a practical manufacturing advantage.
5. The claims cover the marketed product and not merely laboratory prototypes.

A broad claim to "a desonide gel containing a carbomer and glycerin" would likely face substantial prior-art pressure. A more defensible estate could claim a defined polymer, solvent, pH, viscosity range, preservative system, particle-size profile and stability result.

The best strategy is layered protection:

• Composition claims.
• Manufacturing-process claims.
• Container-closure claims.
• Delivered-dose or dispensing claims.
• Method-of-use claims.
• International filings in major dermatology markets.

Geographic coverage should prioritize the United States, European Union, United Kingdom, Japan, Canada, Australia, Brazil, China and South Korea. National patentability standards, regulatory data rules and generic substitution practices differ materially across these markets.

What manufacturing and IP barriers affect a Desonate competitor?

The technical barriers are manageable but not trivial. The highest-risk operations are polymer hydration, neutralization, deaeration, API distribution, pH control and filling.

Carbomer gels can develop air entrapment, viscosity drift or localized polymer clumps if the manufacturing sequence is poorly controlled. Desonide’s low concentration also creates content-uniformity and sampling challenges. Scale-up must control mixing energy, addition rate, hold time and temperature.

The package can be as important as the formulation. A tube is inexpensive and familiar but provides less dosing precision. An airless pump can support a premium product but introduces priming, residual-volume, compatibility and dose-reproducibility requirements.

How does Desonate compare with other topical corticosteroid opportunities?

Desonide occupies a low-potency position. It competes with hydrocortisone products at the lower end of potency and with stronger corticosteroids when more pronounced anti-inflammatory activity is required.

Product category	Relative positioning	Excipient opportunity
Hydrocortisone creams and ointments	Lower-cost, lower-potency alternatives	Cosmetic feel and OTC-oriented convenience
Desonide gel	Low-potency prescription gel	Pediatric, facial and sensitive-skin vehicle differentiation
Medium-potency corticosteroid creams	Higher efficacy for more severe disease	Less suitable for prolonged pediatric or facial use
Nonsteroidal topical agents	Steroid-sparing alternatives	Higher-cost differentiation and chronic-use positioning
Compounded dermatologic gels	Customizable but variable	Niche formulation and specialty-pharmacy channels

Desonate’s principal advantage is the combination of low corticosteroid potency and a cosmetically acceptable gel. Its principal vulnerability is substitution by lower-priced generics and alternative dosage forms.

Key Takeaways

• Desonate is a desonide 0.05% prescription hydrogel for mild-to-moderate atopic dermatitis.
• Its reference vehicle uses carbomer, glycerin, propylene glycol, methylparaben, edetate disodium, purified water and sodium hydroxide.
• The strongest excipient opportunities are preservative-free systems, lower-propylene-glycol vehicles, improved rheology and metered-dose packaging.
• Formulation patents should claim defined composition ranges tied to stability, delivery, tolerability or dispensing results.
• Generic competition is the principal exclusivity risk for a mature desonide product.
• Commercial differentiation must come from patient experience, pediatric usability, delivery precision, packaging or payer strategy.
• Manufacturing know-how around carbomer processing, pH control, API uniformity and filling can create practical barriers even when the formulation concept is not highly novel.
• The FDA Orange Book and current patent records should control any launch, licensing or litigation assessment involving NDA 021844.

FAQs

Is Desonate a cream, ointment or gel?

Desonate is a topical gel containing desonide 0.05%. It is not an ointment or conventional cream.

Which excipient in Desonate creates the gel structure?

Carbomer 934P is the principal gelling polymer. Sodium hydroxide neutralizes the polymer and helps establish the final gel viscosity.

Can methylparaben be removed from a Desonate generic?

It can be removed only if the alternative formulation and packaging maintain microbiological quality, stability, drug performance and regulatory acceptability.

Is propylene glycol important to Desonate performance?

Yes. Propylene glycol can support desonide solubilization, hydration and dermal delivery. Removing it may improve tolerability but can change drug release and skin penetration.

Is a preservative-free Desonate formulation commercially defensible?

Yes, if the formulation is paired with an effective package and supported by stability, microbiological, dose-delivery and comparative performance data. The defensibility is strongest when the formulation and container-closure system are claimed together.

References

1. U.S. Food and Drug Administration. (n.d.). Desonate (desonide) gel, 0.05% prescribing information. FDA/DailyMed.

2. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations. FDA Orange Book.

3. U.S. Food and Drug Administration. (n.d.). Approved drug products and patent and exclusivity information. FDA Orange Book.

4. U.S. Food and Drug Administration. (2022). Product-specific guidance for desonide topical products. FDA.

5. U.S. Pharmacopeial Convention. (2024). United States Pharmacopeia and National Formulary. USP.